Retrospective Cohort Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Aug 15, 2023; 15(8): 1436-1450
Published online Aug 15, 2023. doi: 10.4251/wjgo.v15.i8.1436
Comparison of clinicopathological characteristics and survival outcomes between gallbladder mucinous adenocarcinoma and gallbladder adenocarcinoma: A propensity score-matched study
Wen-Wei Yang, Yu-Ting Fang, Ya-Ru Niu, Yong-Kun Sun
Wen-Wei Yang, Yu-Ting Fang, Ya-Ru Niu, Yong-Kun Sun, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Yong-Kun Sun, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Hebei Cancer Hospital, Langfang 065001, Hebei Province, China
Author contributions: Yang WW contributed to the study design, data collection and analysis, and manuscript composition; Fang YT and Niu YR helped to perform and check the statistical analysis; Sun YK contributed to proofreading and final approval of the article; All authors read and approved the final version.
Supported by The National Key Research and Development Program of China, No. 2021YFF1201300.
Institutional review board statement: As the SEER database is publicly available and de-identified, therefore, the ethical approval was exempted by the ethics committee of our hospital.
Informed consent statement: The SEER database is a public-use database. After submitting a request to the SEER database project and obtaining permission, data freely downloaded from the SEER database did not require patients’ informed consent or institutional approval.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at email address. Participants gave informed consent for data sharing.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yong-Kun Sun, MD, Professor, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China. hsunyk@cicams.ac.cn
Received: March 25, 2023
Peer-review started: March 25, 2023
First decision: May 22, 2023
Revised: June 3, 2023
Accepted: June 19, 2023
Article in press: June 19, 2023
Published online: August 15, 2023
Processing time: 138 Days and 4.6 Hours
Core Tip

Core Tip: Gallbladder mucinous adenocarcinoma (GBMAC) is a rare subtype of gallbladder adenocarcinoma (GBAC), with limited knowledge of its survival outcomes. Based on a large database, we compared the clinicopathological characteristics of GBMAC with typical GBAC and identified prognostic factors for GBMAC. The results showed that the biological behaviors of GBMAC are significantly different from typical GBAC, while survival outcomes for GBMAC patients were not worse than those for typical GBAC patients. Surgery, chemotherapy, and lower American Joint Committee on Cancer stage were associated with better survival outcomes.